**Inclusion/Exclusion Criteria**

The following criteria for evidence inclusion for the MEDS Model Analysis was determined through the guidance of the BCBS Plans’ executive and clinical pharmacists**.**

**Inclusion Criteria**

|  |  |
| --- | --- |
| **Patient Population** | * Individuals ages 12 years or older with moderate to severe allergic asthma or eosinophilic asthma * Randomized Controlled Trials: At least 50 patients |
| **Intervention** | * Omalizumab (Xolair) * Dupilumab (Dupixent) * Mepolizumab (Nucala) * Reslizumab (Cinqair) * Benralizumab (Fasenra) |
| **Comparator** | * Head to Head * Standard of Care treatment with inhaled corticosteroids (ICS) and at least one additional controller agent |
| **Outcomes** | Efficacy Outcomes:   * Acute exacerbation of asthma (30% weight) * Rate of Hospitalization/Emergency Department Visit (70% weight)   Safety Outcomes   * Discontinuation (70% weight) * Severe Adverse Events (30% weight) |
| **Timing** | 12 weeks – 1 year |
| **Setting** | Outpatient |

**Exclusion Criteria**

* Studies involving patients under 12
* Single-arm studies
* Open label long term extension studies (unless the study reported the blinded phase before crossover)
* Randomized controlled trials with sample size of less than 50 patients